Mingjun Zhang

1.0k total citations
67 papers, 645 citations indexed

About

Mingjun Zhang is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mingjun Zhang has authored 67 papers receiving a total of 645 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 19 papers in Molecular Biology and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mingjun Zhang's work include RNA modifications and cancer (9 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Mingjun Zhang is often cited by papers focused on RNA modifications and cancer (9 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Mingjun Zhang collaborates with scholars based in China, United States and Iran. Mingjun Zhang's co-authors include Jinyu Pan, Dian Liu, Fengshuang An, Xuyang Wang, Tao Jin, Jingjing Tian, Ming Liu, Zhendong Chen, Wanhu Li and Ming Liu and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Mingjun Zhang

54 papers receiving 639 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mingjun Zhang China	13	269	111	110	101	101	67	645
Li Wei China	12	339 1.3×	146 1.3×	118 1.1×	108 1.1×	93 0.9×	40	794
Kui Chen China	14	233 0.9×	61 0.5×	157 1.4×	225 2.2×	106 1.0×	40	748
Michael G. Sugiyama Canada	11	257 1.0×	70 0.6×	83 0.8×	61 0.6×	61 0.6×	20	640
Daniel J. Herr United States	16	307 1.1×	45 0.4×	82 0.7×	133 1.3×	69 0.7×	41	701
Brian Tieu United States	10	254 0.9×	286 2.6×	102 0.9×	178 1.8×	91 0.9×	12	929
Jesús Fuentes‐Antrás Spain	14	240 0.9×	136 1.2×	330 3.0×	112 1.1×	93 0.9×	43	740
Xin Gu China	16	372 1.4×	99 0.9×	83 0.8×	40 0.4×	96 1.0×	39	698
Pippa F. Cosper United States	15	286 1.1×	75 0.7×	127 1.2×	97 1.0×	91 0.9×	26	699
Katia Galan Switzerland	17	300 1.1×	42 0.4×	93 0.8×	165 1.6×	74 0.7×	19	799
Mohamed I. Saad Australia	17	321 1.2×	148 1.3×	127 1.2×	22 0.2×	119 1.2×	34	791

Countries citing papers authored by Mingjun Zhang

Since Specialization

Citations

This map shows the geographic impact of Mingjun Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mingjun Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mingjun Zhang more than expected).

Fields of papers citing papers by Mingjun Zhang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mingjun Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mingjun Zhang. The network helps show where Mingjun Zhang may publish in the future.

Co-authorship network of co-authors of Mingjun Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Mingjun Zhang. A scholar is included among the top collaborators of Mingjun Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mingjun Zhang. Mingjun Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yao, Senbang, Jingjing Zhao, Huirong Shi, et al.. (2025). Expression of inflammatory states in response to psychological distress in breast cancer survivors and its relationship to subjective memory function complaints. BMC Women s Health. 25(1). 140–140.

Ye, Dingwei, Shusuan Jiang, Yuan Fang, et al.. (2025). Efficacy and safety of sacituzumab tirumotecan monotherapy in patients with advanced urothelial carcinoma who progressed on or after prior anti-cancer therapies: Report from the phase 1/2 MK-2870-001 study.. Journal of Clinical Oncology. 43(5_suppl). 796–796. 5 indexed citations

Ge, Han, et al.. (2025). Physical Activity and Depression in Breast Cancer Patients: Mechanisms and Therapeutic Potential. Current Oncology. 32(2). 77–77. 3 indexed citations

Chen, Kai, Mingjun Zhang, Yuyan Liu, et al.. (2025). ZnO@PVDF/CS Piezoelectric Nanofibrous Membrane Promotes the Healing of Infected Wounds Stimulated by Low-Intensity Pulsed Ultrasound. ACS Applied Materials & Interfaces. 17(49). 66518–66533.

Tan, Yiqing, Yiping Yang, Mingjun Zhang, et al.. (2025). IRF4 as a molecular biomarker in pan-cancer through multiple omics integrative analysis. Analytical Methods. 17(16). 3183–3201.

Chen, Chanjuan, et al.. (2025). Long-Term and Sustained Remission of Advanced Triple-Negative Breast Cancer with Large Chest Wall Lesions after Transient Chemoimmunotherapy: A Case Report. Case Reports in Oncology. 18(1). 198–205.

Wang, Bulei, Mingjun Zhang, Bingyong Mao, et al.. (2024). Enhancing the anti-fatigue effect of ginsenoside extract by Bifidobacterium animalis subsp. lactis CCFM1274 fermentation through biotransformation of Rb1, Rb2 and Rc to Rd. Food Bioscience. 62. 105251–105251. 4 indexed citations

Zhang, Yaxiong, Liang Han, Wei Jiang, et al.. (2024). Chidamide plus envafolimab as subsequent treatment in advanced non‐small cell lung cancer patients resistant to anti‐PD‐1 therapy: A multicohort, open‐label, phase II trial with biomarker analysis. Cancer Medicine. 13(7). e7175–e7175. 3 indexed citations

Yang, Huijuan, Jian Zhang, Rujiao Liu, et al.. (2024). Efficacy and safety of 9 MW2821, an antibody-drug conjugate targeting Nectin-4 monotherapy, in patients with recurrent or metastatic cervical cancer: A multicenter, open-label, phase I/II study. Gynecologic Oncology. 190. S22–S23. 1 indexed citations

10.

He, Zhisong, Mingjun Zhang, Shusuan Jiang, et al.. (2024). BGB-A317-212: A multicenter, open-label, phase II study to evaluate the efficacy and safety of tislelizumab in combination with lenvatinib in patients with selected solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2610–2610. 1 indexed citations

11.

Zhang, Yuting, et al.. (2024). Efficacy and safety of nanoparticle albumin‑bound paclitaxel compared with solvent‑based paclitaxel in adjuvant therapy for breast cancer: A retrospective study. Oncology Letters. 28(5). 509–509.

12.

Yu, Yongfeng, Yan Yu, Yan Zhang, et al.. (2024). Tifcemalimab combined with toripalimab and chemotherapy as 1st line treatment for extensive-stage small cell lung cancer (ES-SCLC): A phase Ib/II, open-label study.. Journal of Clinical Oncology. 42(16_suppl). 8089–8089. 3 indexed citations

13.

Cheng, Ying, Lin Wu, Yong Fang, et al.. (2024). Abstract CT248: Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2 mutant non-small cell lung cancer (NSCLC): primary analysis from the Phase 2 DESTINY-Lung05 (DL-05) trial. Cancer Research. 84(7_Supplement). CT248–CT248. 5 indexed citations

14.

Zhang, Mingjun, Shuai Chen, Huijuan Liu, et al.. (2024). Grifola frondosa polysaccharide's therapeutic potential in oxazolone-induced ulcerative colitis. Carbohydrate Polymers. 344. 122517–122517. 12 indexed citations

15.

Wang, Feng, Junjie Peng, Xinjun Liang, et al.. (2024). First-line serplulimab plus HLX04 and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: A phase 2/3 study.. Journal of Clinical Oncology. 42(16_suppl). 3569–3569. 2 indexed citations

16.

Wang, Tao, Shuo Chen, Ziliang Wang, et al.. (2023). KIRREL promotes the proliferation of gastric cancer cells and angiogenesis through the PI3K/AKT/mTOR pathway. Journal of Cellular and Molecular Medicine. 28(1). e18020–e18020. 7 indexed citations

17.

Zhang, Mingjun, Zhendong Chen, Yang Yang, et al.. (2017). Pretreatment with different doses of dexamethasone in the prevention of docetaxel-induced hypersensitivity.. PubMed. 30(1). 61–65. 3 indexed citations

18.

Zhang, Wen, Lu Zhang, Yongxi Chen, et al.. (2014). Identification of Nestin as a Urinary Biomarker for Acute Kidney Injury. American Journal of Nephrology. 39(2). 110–121. 14 indexed citations

19.

Zhang, Yongliang, Hongyi Li, Songcai Liu, et al.. (2009). PLGA Microsphere-Mediated Growth Hormone Release Hormone Expression Induces Intergenerational Growth. Animal Biotechnology. 20(3). 124–132. 2 indexed citations

20.

Liu, Songcai, Mingjun Zhang, Qianqian Zhang, et al.. (2007). The Construction of GHRH Gene Expression Vector Based on RNA Replicon and Its Expression in 293 Cell. 395–399. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact